Omega-3s may soon be back in the limelight thanks to a national publicity campaign by GOED.
The Global Organization for EPA and DHA Omega-3s (GOED; Salt Lake City) is moving forward with its national campaign to boost omega-3 sales recovery. Scheduled to launch on March 16, the national campaign will utilize television, digital media, public relations efforts, and in-store advertising in hopes of reminding the public about omega-3s.
GOED had initially planned to postpone the launch pending further financial support from the larger omega-3 industry of the GOED-led Omega-3 Coalition and sales campaign, but the association now says it will move ahead with the national launch following the campaign’s successful test run in North Carolina last fall.
In February, Ellen Schutt, GOED’s communications director, told Nutritional Outlook that “the omega-3 coalition was hoping to launch a national rollout in mid-March, but plans were on hold pending the commitment of additional funds from interested industry players.”
At last week’s Natural Products Expo West trade show, GOED Executive Director Adam Ismail said that the upcoming outreach campaign will run for 10-12 weeks and include in-store advertising at 16,000 participating retailers. Last fall’s four-week test campaign in Charlotte, North Carolina revealed that in-store advertising, television, and digital media were more effective at increasing awareness than billboards or print media, said Ismail. He expects the in-store advertising of the national campaign to extend beyond the 10-12 week television advertising period, and the public relations component will be ongoing throughout the year.
Ismail highlighted the importance of keeping omega-3s at the top of consumers’ minds.
“Our industry by and large doesn’t spend a lot on advertising. We’ve been very lucky and fortunate because the growth was fueled for 20 years by positive science getting in the media.” Unfortunately, he says, fewer positive, large-scale omega-3 trials have been published in recent years, explaining that “the big cause of the downturn was basically consumers forgetting about omega-3s.”
“If the media isn’t writing about these positive stories about omega-3s, then we can fill the gap here,” said Ismail. “The public relations component of it is to reach out to media and point out to them that there are still positive stories about omega 3, they’re just not writing about it.”
Additionally, a wave of highly publicized negative studies, including a much criticized prostate cancer study also took their toll on market sales, leading to steep declines over the last year and a half.
“Often times, it’s just [consumers] need a trigger. There’s a trigger that reminds them ‘Oh yeah, I used to take fish oil. I liked it. I felt better. I need to keep taking it.’ It’s really truly just reminding,” said Ismail. “When we did the Charlotte test, the most effective vehicle in terms of improving consumer purchase intent was the in-store advertising, and I think that really speaks to how consumers need that reminder.”
So far in 2015, Ismail saw a slight improvement in the decline of the omega-3 market. He said it’s performing “fairly well” in non-retail channels but still down about 2% in retail channels.
“It’s a good environment we think to launch a campaign, because the market’s coming back towards a break-even flat growth,” said Ismail.
Read more:
Omega-3 DHA and EPA: 2015 Ingredients to Watch for Food, Beverage, Supplements
Michael Crane
Associate Editor
Nutritional Outlook magazine
michael.crane@ubm.com
Photo © iStockphoto.com/Rixipix
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
Krill oil supplementation raises Omega-3 Index of Lupus patients in recent study
July 16th 2024The study was conducted at 20 research centers in the United States by Aker BioMarine and the Lupus Clinical Investigators Network with oversight by Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.